000288814 001__ 288814
000288814 005__ 20241220114044.0
000288814 0247_ $$2doi$$a10.1007/s00018-024-05126-1
000288814 0247_ $$2pmid$$apmid:38436764
000288814 0247_ $$2pmc$$apmc:PMC10912141
000288814 0247_ $$2ISSN$$a1420-682X
000288814 0247_ $$2ISSN$$a0014-4754
000288814 0247_ $$2ISSN$$a1420-9071
000288814 0247_ $$2altmetric$$aaltmetric:160329026
000288814 037__ $$aDKFZ-2024-00485
000288814 041__ $$aEnglish
000288814 082__ $$a610
000288814 1001_ $$aLiu, Kaijing$$b0
000288814 245__ $$aDynamic YAP expression in the non-parenchymal liver cell compartment controls heterologous cell communication.
000288814 260__ $$aCham (ZG)$$bSpringer International Publishing AG$$c2024
000288814 3367_ $$2DRIVER$$aarticle
000288814 3367_ $$2DataCite$$aOutput Types/Journal article
000288814 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726657409_8429
000288814 3367_ $$2BibTeX$$aARTICLE
000288814 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000288814 3367_ $$00$$2EndNote$$aJournal Article
000288814 520__ $$aThe Hippo pathway and its transcriptional effectors yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are targets for cancer therapy. It is important to determine if the activation of one factor compensates for the inhibition of the other. Moreover, it is unknown if YAP/TAZ-directed perturbation affects cell-cell communication of non-malignant liver cells.To investigate liver-specific phenotypes caused by YAP and TAZ inactivation, we generated mice with hepatocyte (HC) and biliary epithelial cell (BEC)-specific deletions for both factors (YAPKO, TAZKO and double knock-out (DKO)). Immunohistochemistry, single-cell sequencing, and proteomics were used to analyze liver tissues and serum.The loss of BECs, liver fibrosis, and necrosis characterized livers from YAPKO and DKO mice. This phenotype was weakened in DKO tissues compared to specimens from YAPKO animals. After depletion of YAP in HCs and BECs, YAP expression was induced in non-parenchymal cells (NPCs) in a cholestasis-independent manner. YAP positivity was detected in subgroups of Kupffer cells (KCs) and endothelial cells (ECs). The secretion of pro-inflammatory chemokines and cytokines such as C-X-C motif chemokine ligand 11 (CXCL11), fms-related receptor tyrosine kinase 3 ligand (FLT3L), and soluble intercellular adhesion molecule-1 (ICAM1) was increased in the serum of YAPKO animals. YAP activation in NPCs could contribute to inflammation via TEA domain transcription factor (TEAD)-dependent transcriptional regulation of secreted factors.YAP inactivation in HCs and BECs causes liver damage, and concomitant TAZ deletion does not enhance but reduces this phenotype. Additionally, we present a new mechanism by which YAP contributes to cell-cell communication originating from NPCs.
000288814 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000288814 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000288814 650_7 $$2Other$$aCholangiocyte
000288814 650_7 $$2Other$$aEndothelial cell
000288814 650_7 $$2Other$$aHepatocyte
000288814 650_7 $$2Other$$aHippo pathway
000288814 650_7 $$2Other$$aKupffer cell
000288814 650_7 $$2Other$$aLiver damage
000288814 650_7 $$2Other$$aProteomics
000288814 650_7 $$2Other$$aSingle-cell analysis
000288814 650_7 $$2Other$$aTAZ
000288814 650_7 $$2NLM Chemicals$$aLigands
000288814 650_2 $$2MeSH$$aAnimals
000288814 650_2 $$2MeSH$$aMice
000288814 650_2 $$2MeSH$$aEndothelial Cells
000288814 650_2 $$2MeSH$$aLigands
000288814 650_2 $$2MeSH$$aLiver
000288814 650_2 $$2MeSH$$aHepatocytes
000288814 650_2 $$2MeSH$$aCell Communication
000288814 7001_ $$aWehling, Lilija$$b1
000288814 7001_ $$aWan, Shan$$b2
000288814 7001_ $$aWeiler, Sofia M E$$b3
000288814 7001_ $$aTóth, Marcell$$b4
000288814 7001_ $$aIbberson, David$$b5
000288814 7001_ $$aMarhenke, Silke$$b6
000288814 7001_ $$0P:(DE-He78)86c8c6c90abd00c209e39736da1ec1fd$$aAli, Adnan$$b7$$udkfz
000288814 7001_ $$0P:(DE-He78)1c6d6ca22cc31cb79e6e1f5277ef06e0$$aLam, Macrina$$b8$$udkfz
000288814 7001_ $$aGuo, Te$$b9
000288814 7001_ $$aPinna, Federico$$b10
000288814 7001_ $$aPedrini, Fabiola$$b11
000288814 7001_ $$aDamle-Vartak, Amruta$$b12
000288814 7001_ $$aDropmann, Anne$$b13
000288814 7001_ $$aRose, Fabian$$b14
000288814 7001_ $$aColucci, Silvia$$b15
000288814 7001_ $$aCheng, Wenxiang$$b16
000288814 7001_ $$aBissinger, Michaela$$b17
000288814 7001_ $$aSchmitt, Jennifer$$b18
000288814 7001_ $$aBirner, Patrizia$$b19
000288814 7001_ $$aPoth, Tanja$$b20
000288814 7001_ $$0P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9$$aAngel, Peter$$b21$$udkfz
000288814 7001_ $$aDooley, Steven$$b22
000288814 7001_ $$aMuckenthaler, Martina U$$b23
000288814 7001_ $$aLongerich, Thomas$$b24
000288814 7001_ $$aVogel, Arndt$$b25
000288814 7001_ $$0P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5$$aHeikenwälder, Mathias$$b26$$udkfz
000288814 7001_ $$aSchirmacher, Peter$$b27
000288814 7001_ $$00000-0002-2462-1229$$aBreuhahn, Kai$$b28
000288814 773__ $$0PERI:(DE-600)1458497-9$$a10.1007/s00018-024-05126-1$$gVol. 81, no. 1, p. 115$$n1$$p115$$tCellular and molecular life sciences$$v81$$x1420-682X$$y2024
000288814 8564_ $$uhttps://inrepo02.dkfz.de/record/288814/files/s00018-024-05126-1.pdf
000288814 8564_ $$uhttps://inrepo02.dkfz.de/record/288814/files/s00018-024-05126-1.pdf?subformat=pdfa$$xpdfa
000288814 909CO $$ooai:inrepo02.dkfz.de:288814$$pVDB
000288814 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)86c8c6c90abd00c209e39736da1ec1fd$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000288814 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1c6d6ca22cc31cb79e6e1f5277ef06e0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000288814 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000288814 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5$$aDeutsches Krebsforschungszentrum$$b26$$kDKFZ
000288814 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000288814 9141_ $$y2024
000288814 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-21$$wger
000288814 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-21$$wger
000288814 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000288814 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000288814 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000288814 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000288814 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000288814 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000288814 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000288814 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2023-10-21
000288814 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000288814 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000288814 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000288814 9201_ $$0I:(DE-He78)F180-20160331$$kF180$$lChronische Entzündung und Krebs$$x0
000288814 9201_ $$0I:(DE-He78)D440-20160331$$kD440$$lChronische Entzündung und Krebs$$x1
000288814 9201_ $$0I:(DE-He78)A100-20160331$$kA100$$lA100 Signaltransduktion/ Wachstumskontrolle$$x2
000288814 980__ $$ajournal
000288814 980__ $$aVDB
000288814 980__ $$aI:(DE-He78)F180-20160331
000288814 980__ $$aI:(DE-He78)D440-20160331
000288814 980__ $$aI:(DE-He78)A100-20160331
000288814 980__ $$aUNRESTRICTED